Literature DB >> 33787670

Efficacy of short-term moderate or high-dose statin therapy for the prevention of contrast-induced nephropathy in high-risk patients with chronic kidney disease: systematic review and meta-analysis.

Yan-Lin Zhou1, Li-Qun Chen1, Xiao-Gang Du1.   

Abstract

Although previous studies have indicated that statin therapy can effectively prevent the development of CIN, this observation remains controversial, especially in high-risk patients. A meta-analysis was performed to evaluate the efficacy of statin pretreatment for preventing the development of CIN in patients with chronic kidney disease (CKD) and to determine its effectiveness in various subgroups. We searched the online databases PubMed, EMBASE, and the Cochrane Library. RCTs that involved the comparison of the short-term moderate or high-dose statin pretreatment with placebo for CIN prevention in CKD patients undergoing angiography were included. The primary outcome was CIN prevalence. Seven RCTs comprising 4256 participants were investigated in this analysis. The risk of developing CIN in patients pretreated with statins was significantly lower than that in patients pretreated with placebo (RR=0.57, 95%CI=0.43-0.76, p=0.000). The SCr values of the statin group, when analyzed 48h after angiography were lower than those of the placebo group ((SMD=-0.15, 95% CI=-0.27 to -0.04, p=0.011). In the subgroup analysis, statin pretreatment could decrease the risk of CIN in CKD patients with DM (RR=0.54, 95% CI=0.39-0.76, p=0.000), but not in CKD patients without DM (RR=0.84, 95% CI=0.44-1.60, p=0.606). The efficacy of atorvastatin for preventing CIN was consistent with that observed with the use of rosuvastatin. The risk ratios (RR) were 0.51 (95% CI=0.32-0.81, p=0.004) and 0.60 (95% CI=0.41-0.88, p=0.009), respectively. Our study demonstrated that statin pretreatment could prevent the development of CIN in CKD patients. However, subgroup analysis demonstrated that statin pretreatment, despite being effective in preventing CIN in patients with CKD and DM, was not helpful for CKD patients without DM. Rosuvastatin and atorvastatin exhibited similar preventive effects with respect to CIN.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33787670      PMCID: PMC7955149          DOI: 10.6061/clinics/2021/e1876

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  32 in total

1.  Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?

Authors:  Richard W Katzberg; Jeffrey H Newhouse
Journal:  Radiology       Date:  2010-07       Impact factor: 11.105

Review 2.  Pathophysiology of contrast-induced nephropathy.

Authors:  James Tumlin; Fulvio Stacul; Andy Adam; Christoph R Becker; Charles Davidson; Norbert Lameire; Peter A McCullough
Journal:  Am J Cardiol       Date:  2006-02-17       Impact factor: 2.778

Review 3.  Statins and contrast-induced acute kidney injury with coronary angiography.

Authors:  Sumeet Gandhi; Wassim Mosleh; Husam Abdel-Qadir; Michael E Farkouh
Journal:  Am J Med       Date:  2014-05-20       Impact factor: 4.965

4.  Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.

Authors:  Yaling Han; Guoying Zhu; Lixian Han; Fengxia Hou; Weijian Huang; Huiliang Liu; Jihong Gan; Tiemin Jiang; Xiaoyan Li; Wei Wang; Shifang Ding; Shaobin Jia; Weifeng Shen; Dongmei Wang; Ling Sun; Jian Qiu; Xiaozeng Wang; Yi Li; Jie Deng; Jing Li; Kai Xu; Bo Xu; Roxana Mehran; Yong Huo
Journal:  J Am Coll Cardiol       Date:  2013-09-26       Impact factor: 24.094

5.  The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy.

Authors:  Yanjuan Hou; Yonghong Shi; Baosheng Han; Xuqian Liu; Xi Qiao; Yue Qi; Lihua Wang
Journal:  Nephrol Dial Transplant       Date:  2018-11-01       Impact factor: 5.992

Review 6.  Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.

Authors:  Michele Andreucci; Richard Solomon; Adis Tasanarong
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

7.  Efficacy of Atorvastatin in Prevention of Contrast-induced Nephropathy in High-risk Patients Undergoing Angiography: A Double-blind Randomized Controlled Trial.

Authors:  Maaz Hussain Syed; Prakash Narayan Khandelwal; Vijay R Thawani; S S Katare
Journal:  J Pharmacol Pharmacother       Date:  2017 Apr-Jun

8.  Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway.

Authors:  Rongzheng Yue; Chuan Zuo; Jing Zeng; Baihai Su; Ye Tao; Songmin Huang; Rui Zeng
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

9.  Preventive Effect of Atorvastatin (80 mg) on Contrast-Induced Nephropathy After Angiography in High-Risk Patients: Double-Blind Randomized Clinical Trial.

Authors:  Arezoo Khosravi; Mitra Dolatkhah; Hesam Sadat Hashemi; Zohreh Rostami
Journal:  Nephrourol Mon       Date:  2016-03-08

10.  Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures.

Authors:  Pierre Aubry; Georges Brillet; Laura Catella; Aurélie Schmidt; Stève Bénard
Journal:  BMC Nephrol       Date:  2016-11-08       Impact factor: 2.388

View more
  1 in total

Review 1.  The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy.

Authors:  Eunjung Cho; Gang-Jee Ko
Journal:  Diagnostics (Basel)       Date:  2022-01-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.